Janssen v. Celltrion: District Court Schedules Hearing on Motion to Dismiss

more+
less-

As we previously reported, Celltrion has moved to dismiss Janssen’s claim of infringement of the ’083 patent, the sole remaining patent in the case since the district court entered partial final judgment with respect to the ’471 patent.  On October 7, 2016, Judge Wolf issued an order instructing the parties, among other things, to continue to meet and confer and that, if Celltrion does not withdraw its motion to dismiss, a hearing on the motion will be held on December 21-22, 2016.  The order also provided further instructions about the parties’ pretrial submissions and additional pretrial conferences and reaffirmed that trial will begin on February 13, 2017.  According to the case docket, 10 days between February 13 and 24 are currently reserved for the jury trial, though the court’s order instructs the parties to include a statement in their January 12, 2017 pretrial memorandum of the number of trial days the trial will require, to aid the court in establishing time limits.

Stay tuned to Big Molecule Watch for further updates about this case.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

more+
less-

Goodwin on:

JD Supra Readers' Choice 2016 Awards
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×
Loading...
×
×